[go: up one dir, main page]

PT743856E - Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros - Google Patents

Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros

Info

Publication number
PT743856E
PT743856E PT95912577T PT95912577T PT743856E PT 743856 E PT743856 E PT 743856E PT 95912577 T PT95912577 T PT 95912577T PT 95912577 T PT95912577 T PT 95912577T PT 743856 E PT743856 E PT 743856E
Authority
PT
Portugal
Prior art keywords
heteropolymes
antigen
auto
treatment
those
Prior art date
Application number
PT95912577T
Other languages
English (en)
Inventor
Ronald P Taylor
Polly J Ferguson
Edward N Martin
Craig J Reist
Kirsten Greene
Cyd Johnson
William S Sutherland
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of PT743856E publication Critical patent/PT743856E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT95912577T 1994-02-28 1995-02-28 Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros PT743856E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20257294A 1994-02-28 1994-02-28

Publications (1)

Publication Number Publication Date
PT743856E true PT743856E (pt) 2003-12-31

Family

ID=22750436

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95912577T PT743856E (pt) 1994-02-28 1995-02-28 Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros

Country Status (11)

Country Link
US (2) US5879679A (pt)
EP (1) EP0743856B1 (pt)
JP (1) JPH09509572A (pt)
AT (1) ATE245030T1 (pt)
AU (1) AU696964B2 (pt)
CA (1) CA2183535A1 (pt)
DE (1) DE69531290T2 (pt)
DK (1) DK0743856T3 (pt)
ES (1) ES2207646T3 (pt)
PT (1) PT743856E (pt)
WO (1) WO1995022977A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696964B2 (en) * 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same
CN1399562A (zh) * 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
AU4155602A (en) * 2000-11-01 2002-06-18 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
WO2002075275A2 (en) * 2001-03-15 2002-09-26 Elusys Therapeutics, Inc. Polyclonal populations of bispecific molecules and methods of production and uses thereof
WO2003007971A1 (en) * 2001-07-17 2003-01-30 University Of Virginia Patent Foundation Improved heteropolymer complexes and methods for their use
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2003018774A2 (en) * 2001-08-29 2003-03-06 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
EP1576100A4 (en) * 2002-05-13 2007-08-22 Elusys Therapeutics Inc PURIFIED COMPOSITION OF BISPECIFIC MOLECULES AND METHODS OF PRODUCING THE SAME
AU2003243556A1 (en) * 2002-06-13 2003-12-31 Cygene, Inc. Methods and compositions for in vivo clearance of pathogens
CA2499081A1 (en) * 2002-09-16 2004-04-22 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
JP2007525446A (ja) * 2003-03-28 2007-09-06 エルシス セラピューティクス, インク. 抗体活性の転換のための方法及び組成物
US20040258683A1 (en) * 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
CA2524771A1 (en) 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor
US9493538B2 (en) * 2004-05-28 2016-11-15 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
EP1814918A1 (en) * 2004-10-29 2007-08-08 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
EP1945261A4 (en) 2005-11-07 2010-05-12 Scripps Research Inst COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
FR2968304B1 (fr) * 2010-12-01 2014-03-14 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux epaississants cationiques, exempts d'huile et de tensioactifs, procede pour leur preparation et composition en contenant.
CN110075284A (zh) * 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
EA201691686A1 (ru) 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
JP7278270B2 (ja) * 2017-10-20 2023-05-19 シーエスエル、リミテッド 方法
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
EP4574842A1 (en) * 2023-12-22 2025-06-25 Deutsches Rheuma-Forschungszentrum Berlin Bispecific conjugate for antigen-specific b cell depletion by t cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
AU696964B2 (en) * 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same

Also Published As

Publication number Publication date
EP0743856B1 (en) 2003-07-16
US20020103343A1 (en) 2002-08-01
EP0743856A1 (en) 1996-11-27
EP0743856A4 (en) 2000-04-12
DE69531290T2 (de) 2004-05-13
AU696964B2 (en) 1998-09-24
AU1967795A (en) 1995-09-11
CA2183535A1 (en) 1995-08-31
ATE245030T1 (de) 2003-08-15
JPH09509572A (ja) 1997-09-30
US5879679A (en) 1999-03-09
WO1995022977A1 (en) 1995-08-31
ES2207646T3 (es) 2004-06-01
DE69531290D1 (de) 2003-08-21
DK0743856T3 (da) 2003-11-10

Similar Documents

Publication Publication Date Title
PT743856E (pt) Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
DE69434097D1 (de) Apoptose induzierender monoklonaler antikörper
NO971059L (no) Modifiserte human-C3-proteiner
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
PT89573A (pt) Metodo para a reducao de respostas mediadas por imunoglobulina e
TR199901636T2 (xx) �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
SE8800886D0 (sv) Immunoglobulin conjugates
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
ES2236692T3 (es) Un metodo para prevenir los efectos secundarios y la insensibilidad a los usos terapeuticos de toxinas.
ES552073A0 (es) Un procedimiento para purificar urocinasa